TRI-611

DRUG2 trials

Sponsors

Triana Biomedicines Inc., TRIANA Biomedicines, Inc.

Conditions

ALK-Positive Lung CancerALK-positive NSCLCALK-positive Non-small Cell Lung CancerAdvanced ALK-positive NSCLC

Phase 1

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

RecruitingNCT07491497

TRIANA Biomedicines, Inc.ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer, ALK-positive NSCLC

Start: 2026-03-11End: 2034-01-30Target: 160Updated: 2026-09-03

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

Not yet recruitingCTIS2025-524418-27-00

Triana Biomedicines Inc.Advanced ALK-positive NSCLC

Target: 4Updated: 2026-07-24